Skip to Content

Triplets Frontline Therapy Increases PFS for Patients with Previously Untreated Advanced Renal-Cell Carcinoma

In this MEDtalk, medical oncologist Laurence Albiges presents a phase 3 trial investigating potential benefits of using triplets in frontline therapy for patients with previously untreated advanced renal-cell carcinoma. Results suggest a significantly longer PFS in patients treated with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) and Yervoy (ipilimumab) compared with nivolumab and ipilimumab alone.

Laurence Albiges

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top